Flow Traders U.S.’s Aldeyra Therapeutics ALDX Stock Holding History

Flow Traders U.S.’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-55,521	Closed	-$94K	–	982
2026 Q1	$94K	Buy	+55,521	New	+$243K	﹤0.01%	943

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Flow Traders U.S.'s ALDX Position: Q2 2026 in Review

Flow Traders U.S. sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 55,521 shares — an estimated $94K sold.

Flow Traders U.S. first reported a position in ALDX in Q1 2026 and held it in 1 quarter. The position peaked at $94K in Q1 2026. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Flow Traders U.S. reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
Flow Traders U.S. sold 55,521 Aldeyra Therapeutics shares in Q2 2026, an estimated $94K.
Flow Traders U.S. first reported a position in Aldeyra Therapeutics in Q1 2026 and held it in 1 quarter.
Flow Traders U.S.'s Aldeyra Therapeutics position peaked at $94K in Q1 2026.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Flow Traders U.S.'s 13F filing for Q2 2026, filed 14 Aug 2026.